Search
Search Results
-
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
PurposeHER2 overexpression in breast cancer correlates with poor outcomes. The incorporation of Trastuzumab into the treatment regimen has notably...
-
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)
BackgroundCyclin-dependent kinase 4/6 inhibitors (CDK4/6i) improve the prognosis of hormone receptor-positive HER2-negative advanced/metastatic...
-
Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
Approximately 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2+), conferring a particularly aggressive subtype of the...
-
Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer
PurposeAmong cases of breast cancer, estrogen receptor-positive (ER +), PIK3CA-mutant, HER2- advanced breast cancer stands as a particularly complex...
-
Is neoadjuvant chemotherapy necessary for T2N0-1M0 hormone receptor-positive/HER2-negative breast cancer patients undergoing breast-conserving surgery?
IntroductionFor HR-positive/HER2-negative patients who can undergo breast-conserving surgery (BCS) but have a tumor size of 2–5 cm or 1–3 lymph node...
-
The dynamics of HER2-low expression during breast cancer progression
PurposeLow HER2 expression is emerging as an actionable target for the treatment of breast cancer (BC) with the antibody drug conjugate Trastuzumab...
-
Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole
BackgroundAn open-label, single-arm, Japanese phase 2 study (J-Ph2) investigated the efficacy and safety of first-line (1L) palbociclib...
-
Efficacy and safety of first-line therapy in patients with HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials
PurposeThe numerous first-line treatment regimens for human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC)...
-
Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy
BackgroundBreast cancer presents diverse molecular subtypes affecting treatment strategies. Human epidermal growth factor receptor 2 (HER2)-low,...
-
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
SOLAR-1 and BYLieve trials documented the efficacy of the PI3K-inhibitor alpelisib in pre-treated PIK3CA -mutant, hormone receptor-positive,...
-
Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review
BackgroundPalbociclib in combination with endocrine therapy is approved for treatment of hormone receptor-positive (HR+)/human epidermal growth...
-
Plasma THBS1 as a predictive biomarker for poor prognosis and brain metastasis in patients with HER2-enriched breast cancer
BackgroundThrombospondin-1 (THBS1) is a secretory adhesive glycoprotein involved in the progression of multiple malignancies, including breast...
-
New treatment options for metastatic HER2-low breast cancer
The overexpression of HER2 in breast cancer is a classic example for molecular targeted therapy, and it has been shown that classical anti-HER2...
-
Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2− Metastatic Breast Cancer Treated with Abemaciclib
BackgroundAbemaciclib is the most recent oral cyclin-dependent kinase 4 and 6 inhibitor (CDK4 & 6i) to receive US Food and Drug Administration (FDA)...
-
Impact of molecular subtype and race on HR+, HER2− breast cancer survival
PurposeThere is an urgent need to understand the biological factors contributing to the racial survival disparity among women with hormone...
-
Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?
Purpose of reviewTo summarize the treatment strategies for patients with human epidermal growth factor receptor 2 (HER2)-positive disease and...
-
Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
BackgroundThere is increasing interest in the use of liquid biopsies, but data on longitudinal analyses of circulating tumor DNA (ctDNA) remain...
-
Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database
BackgroundGuideline recommendations for the application of neoadjuvant chemotherapy (NACT) in T2N1M0 stage hormone receptor-positive, HER2-negative...
-
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer
Since the release of the DESTINY-Breast04 (DB-04) trial findings in June 2022, the field of pathology has seen a renaissance of HER2 as a predictive...
-
Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer
PurposeCurrent systemic therapy guidelines for patients with HER2 + breast cancer brain metastases (BCBrM) diverge based on the status of...
